Publications in Therapeutic Drug Monitoring Last 2 Years
Small Changes, Big Consequences? Assessment of the Impact of Design Changes in Microsampling Devices. Boffel L, Stove CP. Ther Drug Monit. 2025 Dec 12. doi: 10.1097/FTD.0000000000001422. Online ahead of print. PMID: 41382331 No abstract available.
To Convert or Not to Convert? Official International Association of Therapeutic Drug Monitoring and Clinical Toxicology Guideline: Considerations and Recommendations for Converting Capillary Blood Microsampling Concentrations to Plasma Concentrations. Boffel L, De Baets H, Heughebaert L, Rispens T, Åsberg A, Shipkova M, de Winter BCM, Moes DJAR, de Vries A, Alffenaar JC, Stove CP. Ther Drug Monit. 2026 Feb 1;48(1):1-26. doi: 10.1097/FTD.0000000000001393. Epub 2025 Nov 5. PMID: 41191790
Toward Clinical Implementation of a Volumetric Absorptive Microsampling-Based Method for Dasatinib and Imatinib Therapeutic Drug Monitoring.
Verougstraete N, Mazure D, Stove CP. Ther Drug Monit. 2025 Dec 1;47(6):740-746. doi: 10.1097/FTD.0000000000001387. Epub 2025 Sep 18. PMID: 40965046
Improvements, Challenges, and the Investigation of Two Unknowns in Arsenic Urine Speciation Analysis by HPLC-ICP-MS: From Development to Post-implementation. Smith K, Genesi BT, Boyd JM, Johnson-Davis KL. Ther Drug Monit. 2025 Dec 23;48(2):235-243. doi: 10.1097/FTD.0000000000001412. PMID: 41348096
Broad-Spectrum Drug Screening Positivity Rates in Pediatrics and Adults: The Reference Laboratory Perspective. Shean RC, Johnson-Davis KL. Ther Drug Monit. 2025 Oct 10;48(2):244-251. doi: 10.1097/FTD.0000000000001400. PMID: 41068998
Smith K, Genesi BT, Boyd JM, Johnson-Davis KL. Improvements, Challenges, and the Investigation of Two Unknowns in Arsenic Urine Speciation Analysis by HPLC-ICP-MS: From Development to Post-implementation. Ther Drug Monit. 2026 Apr 1;48(2):235-243. doi: 10.1097/FTD.0000000000001412. Epub 2025 Dec 23. PMID: 41348096; PMCID: PMC12978725.
Shean RC, Johnson-Davis KL. Broad-Spectrum Drug Screening Positivity Rates in Pediatrics and Adults: The Reference Laboratory Perspective. Ther Drug Monit. 2026 Apr 1;48(2):244-251. doi: 10.1097/FTD.0000000000001400. Epub 2025 Oct 10. PMID: 41068998; PMCID: PMC12978719.
Masuda S, Lemaitre F, Barten MJ, Bergan S, Shipkova M, van Gelder T, Vinks S, Wieland E, Bornemann-Kolatzki K, Brunet M, de Winter B, Dieterlen MT, Elens L, Ito T, Johnson-Davis K, Kunicki PK, Lawson R, Lloberas N, Marquet P, Millan O, Mizuno T, Moes DJAR, Noceti O, Oellerich M, Pattanaik S, Pawinski T, Seger C, van Schaik R, Venkataramanan R, Walson P, Woillard JB, Langman LJ. Everolimus Personalized Therapy: Second Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Ther Drug Monit. 2025 Feb 1;47(1):4-31. doi: 10.1097/FTD.0000000000001250. Epub 2024 Sep 25. PMID: 39331837.
Kunz M, Wagmann L, Schuster M, Götzinger F, Andreas Link, Felix Mahfoud. Unveiling Cardiac Complications: A Case of Amisulpride Overdose Leading to Bradycardia, QT-Prolongation, and Torsade de Pointes Tachycardia. Ther Drug Monit. 2025 Mar 5;47(4):462-465. doi: 10.1097/FTD.0000000000001318. PMID: 40643136
Jacobs CM, Wagmann L, Meyer MR. Sample Matrices for Mass Spectrometry-Based Adherence Monitoring: A Systematic Critical Review. Ther Drug Monit. 2024 Feb 1;46(1):6-15. doi: 10.1097/FTD.0000000000001145. PMID: 37798828
Koppen AJ, Mian P, Sturkenboom MGG. A comprehensive overview of the treatment of acute paracetamol overdose. Ther Drug Monit. 2025 Oct 31. doi: 10.1097/FTD.0000000000001403. Online ahead of print. PMID: 41182883.
Kroes, JH, Poortvliet J, Touw DJ, Oortgiesen B, Sturkenboom MGG. Paracetamol half-life declines over time following an acute overdose. Ther Drug Monit. 2025 Sep 24. doi: 10.1097/FTD.0000000000001395. Online ahead of print. PMID: 40990326.
Nazar M, Kootstra-Ros JE, Touw DJ, Sturkenboom MGG. In vitro study of the effects of acetylcysteine on the international normalized ratio over time. Ther Drug Monit. 2025 Jul 14. doi: 10.1097/FTD.0000000000001356. Online ahead of print. PMID: 40663728.
Steenkamp V, Parkar H, Raphiri B, Neuman MG, Dasgupta A. Herbal Remedies in Global Health Care: Classification, Toxicology, and Clinical Management. Ther Drug Monit. 2025;48:210-219 DOI: 10.1097/FTD.0000000000001417 (IF = 2.4) ) [Special issue dedicated to Dr Sunshine]
Verougstraete N, Mazure D, Stove CP. Toward Clinical Implementation of a Volumetric Absorptive Microsampling-Based Method for Dasatinib and Imatinib Therapeutic Drug Monitoring. Ther Drug Monit 2025;47:740-746.
Van Herteryck C, Reyns T, Jager N, Stove V, Verougstraete N. Addressing Analytical Challenges to Improve Laboratory Consistency in Unbound Flucloxacillin Measurement. Ther Drug Monit 2026; online ahead of print (doi: 10.1097/FTD.0000000000001449)
Jousselin E, Griffeuille P, Petit I, Saint-Marcoux F, El Balkhi S, Védrenne N. Detecting the Undetectable: Analytical Strategies for Novel Psychoactive Substances. Ther Drug Monit. 2026 Apr 1;48(2):160-171. doi: 10.1097/FTD.0000000000001431. Epub 2026 Jan 9. PMID: 41508320.
Bressin P, El Balkhi S, El Hamel C, Yardin C, Guigonis V, Saint-Marcoux F, Ponthier L. Pyrethroid Exposure in Premature Newborns: A Pilot Study on Materno-Fetal Transmission and Early Postnatal Evolution. Ther Drug Monit. 2026 Apr 1;48(2):266-275. doi: 10.1097/FTD.0000000000001407. Epub 2025 Oct 31. PMID: 41182891.
El Balkhi S, Franssen EJF. Twenty Years of Evolution in Toxicology Laboratories: Lessons Learned to Face Upcoming Challenges in Health Care and Society. Ther Drug Monit. 2026 Apr 1;48(2):141-148. doi: 10.1097/FTD.0000000000001409. Epub 2025 Nov 13. PMID: 41232029.
El Balkhi S, Machon C. Toxicology of Heavy Metals in Biological Matrices: A Paradigm Shift From Single-Analyte Measurement to Comprehensive Screening. Ther Drug Monit. 2026 Apr 1;48(2):196-209. doi: 10.1097/FTD.0000000000001416. Epub 2025 Dec 8. PMID: 41358615.
Griffeuille P, El Balkhi S, Dulaurent S, Saint-Marcoux F. Probe Electrospray Ionization Tandem Mass Spectrometry for the Detection and Quantification of Benzodiazepines. Ther Drug Monit. 2024 Aug 1;46(4):522-529. doi: 10.1097/FTD.0000000000001189. Epub 2024 Mar 18. PMID: 38498915.
Stefan C, Jung B, Zhou J, Franssen EJF, Langman LJ, Fu L. Urine Drug Testing: Service Models and Laboratory Practices to Meet Clinical Care Needs. Ther Drug Monit. 2026 Apr 1;48(2):185-195. doi: 10.1097/FTD.0000000000001428. Epub 2026 Feb 23.PMID: 41729621
Lien TNT, Mohamed SMM, van den Bogaard B, Touw DJ, Franssen EJF. Effects of Plasmapheresis on Serum Lithium Levels in an ICU Patient with Bipolar Disorder: A Case Study. Ther Drug Monit. 2024 Jun 1;46(3):281-284. doi: 10.1097/FTD.0000000000001191. PMID: 38723114.
Publication in Compass Last 2 Years
Bennett M. The Illicit Fentanyl Landscape: Trends, Concentrations and Co-Occurrences. Compass, 2026. March; 25(1).
Bennett M. An Alternative Strategy for Detecting Novel Psychoactive Substances in Urine. Compass. 2025 Jun; 24(2).
Steenkamp V. Starting, growing, leading: A scientific journey. COMPASS 2026;25(1) March
Chelsea B Swartchick and Loralie Langman Phosphatidylethanol Measurement: Advantages, Limitations And Future Perspectives. COMPASS 2025;25(41) Dec
Lea Wagmann , Cytotoxicity Testing Of New Psychoactive Substances In Clinical Toxicology COMPASS 2024;23(1) March
Lea Wagmann Award Contribution: In Vitro Biotransformation Of Six Compounds Derived From The Stimulant Prolintane COMPASS 2026;25(soon) June
Practice Guidelines/Standards
Hiemke et al.: Consensus Guidelines for TDM in Neuropsychopharmacology: Update 2017, Pharmacopsychiatry 2018; 51: 9-62
Draft consensus document https://myadlm.org/science-and-research/academy-guidance/guidance-document-comments
